https://www.selleckchem.com/pr....oducts/hmpl-504-azd6
In recent years the use of beta-emitting radiopharmaceuticals for cancer therapy has expanded rapidly following development of therapeutics for neuroendocrine tumors, prostate cancer, and other oncologic malignancies. One emerging beta-emitting radioisotope of interest for therapy is67Cu (t1/2 2.6 d) due to its chemical equivalency with the widely-established positron-emitting isotope64Cu (t1/2 12.7 h). In this work we evaluate both the imaging and dosimetric characteristics of67Cu, as well as producing the first repo
Like
Comment
Share
